

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057

12th May, 2025

To,
Department of Corporate Services,
BSE Limited
Ground Floor, P. J. Towers,
Dalal Street,
Mumbai – 400 001

Scrip Code: 530057

**Subject: Outcome of Board of Directors Meeting of Vivanza Biosciences Limited
("the Company")**

Dear Sir/Madam,

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, 12th May, 2025 at Registered Office of the Company has inter alia considered and approved the following businesses:

- 1. Audited Standalone and Consolidated Financial Results along with Audit Report of the Company for the Quarter and Financial Year ended 31st March, 2025 .**

A copy of the Audited Standalone and Consolidated Financial Results of the Company for the quarter and Financial year ended 31st March, 2025 along with statements of Assets and Liabilities and Auditor's Report are enclosed herewith as **Annexure –A**. These results are also being uploaded on the Company website at www.vivanzabiosciences.com.

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057

2. Appointment of M/s. Rahul Doshi & Co., Chartered Accountants (FRN: 150982W, Membership No. 117160) as Internal Auditor of the Company for the Financial year 2025-26.

The Board, based on the recommendation of Audit Committee in their meeting held today i.e. 12th May, 2025 has approved the appointment of M/s. Rahul Doshi & Co., Chartered Accountants (FRN: 150982W, Membership No. 117160) as Internal Auditor of the Company for the Financial year 2025-26.

The details as required under Regulation 30 of the Listing Regulations, read with SEBI Master Circular Number SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed herewith as **Annexure –B**.

3. Appointment of Mr. Chintan K. Patel, Practicing Company Secretary (Membership No. A31987, COP: 11959) as Secretarial Auditor of the Company for the Financial year 2024-25.

The details as required under Regulation 30 of the Listing Regulations, read with SEBI Master Circular Number SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed herewith as **Annexure –C**.

4. Appointment of Mr. Hitesh Pradeep Rijwani (DIN: 11030634) as an Additional Director (Non- Executive, Independent Director).

The Board, based on the recommendation of Nomination and Remuneration Committee in their meeting held today i.e. 12th May, 2025 has approved the appointment of Mr. Hitesh Rijwani (DIN: 11030634) as an Additional Director (Non- Executive, Independent Director) of the Company, pursuant to Section 149, 150, 152 read with Schedule IV and

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057

Section 161(1) read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and other applicable provisions thereof, for a first term of 5 (five) consecutive years commencing from May 12, 2025, subject to approval of shareholders of the Company to be obtained within three months hereof.

Mr. Mr. Hitesh Pradeep Rijwani will be a Non-Executive, Independent Director and is not related to the Promoter or Promoter Group and fulfils the criteria of independence as required under the provisions of the Companies Act, 2013 and the Rules framed thereunder and the Listing Regulations.

Pursuant to Exchange circular LIST/COMP/14/2018-19 dated June 20, 2018, we hereby confirm that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

The details as required under Regulation 30 of the Listing Regulations, read with SEBI Master Circular Number SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed herewith as **Annexure –D**.

5. Reconstitution of Committees of the Board w.e.f. 12th May, 2025:

The Board in their meeting held today also considered and approved the Reconstitution of Audit Committee, Nomination & Remuneration Committee, Stakeholders Relationship Committee, and Independent Directors Committee, the details of which is annexed as **Annexure- E**.

The Board Meeting Commenced at 5:00 p.m. and concluded at 6:20 p.m.

You are requested to take above information on your record.

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057

Thanking you,

Yours Faithfully,

For, Vivanza Biosciences Limited

SIDDHI JAYENDRA Digitally signed by SIDDHI
SHAH JAYENDRA SHAH
Date: 2025.05.12 18:27:31 +05'30'

Siddhi Shah
Company Secretary & Compliance Officer
Membership No.: A44885

To,
The Board of Directors
M/s Vivanza Biosciences Limited

Opinion

We have audited the accompanying standalone annual financial results of M/s Vivanza Biosciences Limited (hereinafter referred to as 'the Company') for the quarter and year ended March 31, 2025 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

(i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(ii) give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of Net Profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Standalone Financial Results

This Statement have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net loss and other comprehensive income in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.



The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Company, as aforesaid.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the Override of internal control

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement include the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Place: Ahmedabad
Date: 12th May, 2025



For, SHIVAM SONI & Co.
Chartered Accountants
FRN: 152477W

Shivam

CA Shivam Soni
Proprietor
Membership No: 178351
UDIN : 25178351BMIRIM2273

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

CIN : L24110GJ1982PLC005057

Email: info@vivanzabiosciences.com Website : www.vivanzabiosciences.com Ph.no. : 079-26870953

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2025

(Rs. in Lacs except per share data)

Particulars	Quarter Ended			Year Ended	
	31-03-2025	31-12-2024	31-03-2024	31-03-2025	31-03-2024
	Audited	Unaudited	Audited	Audited	Audited
1 Income from Operations					
(a) Revenue from operations	16.96	76.21	229.85	294.28	1441.32
(b) Other Income	1.92	1.03	-2.92	3.46	5.42
Total Income	18.89	77.23	226.93	297.74	1446.73
2 Expenses					
(a) Cost of Materials consumed	0.00	0.00	0.00	0.00	0.00
(b) Purchase of stock-in-trade	17.18	75.35	203.26	266.77	1317.39
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	69.69	-29.05	23.80	-4.29	-18.95
(d) Employee benefits expense	11.25	7.38	6.94	36.73	30.62
(e) Finance Cost	7.92	8.72	9.19	35.08	41.30
(f) Depreciation and amortisation expense	0.28	0.41	1.00	1.40	1.21
(g) Other expenses	8.97	10.57	9.39	31.42	32.27
Total Expenses	115.29	73.38	253.59	367.10	1403.84
3 Profit/(loss) before exceptional items and tax (1-2)	-96.40	3.86	-26.66	-69.36	42.89
4 Exceptional Items	0.00	0.00	0.00	0.00	0.00
5 Profit/(Loss) before tax (3-4)	-96.40	3.86	-26.66	-69.36	42.89
6 Tax Expense					
(a) Current tax	0.00	0.00	11.26	0.00	11.26
(b) Deferred tax	0.14	0.00	-0.11	0.14	-0.11
Total Tax Expenses	0.14	0.00	11.15	0.14	11.15
7 Profit / (Loss) for the period from continuing oprations (5-6)	-96.54	3.86	-37.81	-69.51	31.74
8 Profit (Loss) from discontinuing oprations	0.00	0.00	0.00	0.00	0.00
9 Tax Expense of discontinuing oprations	0.00	0.00	0.00	0.00	0.00
10 Profit (Loss) from discontinuing oprations (after	0.00	0.00	0.00	0.00	0.00
11 Other Comprehensive Income					
A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
Other Comprehensive Income for the period	0.00	0.00	0.00	0.00	0.00
12 Total Comprehensive Income for the period	-96.54	3.86	-37.81	-69.51	31.74
13 Paid-up equity share capital (Face value of Rs. 1/- each)	400	400	400	400	400
14 Other Equity	-	-	-	2.04	71.53
15 Earnings Per Share (before extraordinary items) (not annualised):					
(a) Basic	-0.24	0.01	-0.09	-0.17	0.08
(b) Diluted	-0.24	0.01	-0.09	-0.17	0.08
16 Earnings Per Share (after extraordinary items) (not annualised):					
(a) Basic	-0.24	0.01	-0.09	-0.17	0.08
(b) Diluted	-0.24	0.01	-0.09	-0.17	0.08


Notes:

1. The above standalone audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on **May 09, 2025**. The Audit under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Audit Report does not contain any observation which could have an impact on the results for the quarter/year ended March 31, 2025.


2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. The Company is in the business of Pharmaceuticals and Agro Trading & Consultancy activities.


For, VIVANZA BIOSCIENCES LIMITED


JAYENDRA MEHTA
 MANAGING DIRECTOR
 DIN : 08210602

Date : 12/05/2025
Place : Ahmedabad



VIVANZA BIOSCIENCES LIMITED			
STATEMENT OF STANDALONE ASSETS AND LIABILITIES			
			(Rs.in Lacs)
Particulars		As at 31/03/2025	As at 31/03/2024
A	ASSETS		
	1 Non-current Assets		
(a)	Property , Plant and Equipment	2.06	2.67
(b)	Other Intangible assets	-	-
(c)	Capital work in progress	-	-
(d)	Intangible assets under development	-	-
(e)	Financial Assets :		
(i)	Investments	191.45	191.45
(ii)	Deferred tax assets (Net)	0.06	0.21
(iii)	Loans	-	-
(f)	Other non-current assets	59.33	59.33
	Sub-total - Non-current Assets	252.91	253.66
	2 Current Assets		
(a)	Inventories	184.25	179.96
(b)	Financial Assets :		
(i)	Investments	-	-
(ii)	Trade Receivables	738.59	1,036.68
(iii)	Cash and Cash Equivalents	4.94	9.05
(iv)	Loans	180.49	176.15
(c)	Other current assets	30.03	31.60
	Sub-total - Current Assets	1,138.30	1,433.43
	TOTAL - ASSETS	1,391.21	1,687.10
B	EQUITY AND LIABILITIES		
	Shareholders' Funds		
(a)	Share Capital	400.00	400.00
(b)	Other Equity	2.04	71.53
	Sub-total - Shareholders' Funds	402.04	471.53
	1 Liabilities		
	Non-current Liabilities		
(a)	Financial Liabilities :		
(i)	Borrowings	77.53	77.53
(b)	Deferred Tax Liabilities (Net)	-	-
(c)	Provisions	-	-
(d)	Other Non - Current Liabilities	-	-
	Sub-total - Non-current liabilities	77.53	77.53
	2 Current Liabilities		
(a)	Financial Liabilities :		
(i)	Borrowings	531.73	248.75
(ii)	Trade Payables	321.80	823.47
(iii)	Other Financial Liabilities	-	-
(b)	Provisions	3.80	23.52
(c)	Other Current Liabilities	54.33	42.29
	Sub-total - Current Liabilities	911.64	1,138.03
	TOTAL - EQUITY AND LIABILITIES	1,391.21	1,687.10



[Handwritten signature]

VIVANZA BIOSCIENCES LIMITED
standalone Cashflow Statement

Particulars	(Rs.in Lacs)	
	01-04-2024 to 31-03-2025	01-04-2023 to 31-03-2024
A Cash flow from Operating Activities		
Net Profit Before Tax	(69.36)	42.89
Adjustments for:		
Add Depreciation	1.40	1.21
Less Dividend Income	-	-
Add Interest Expense	35.08	41.30
Less Short Term Capital Gain (Mutual Fund)	-	-
Operating Profit / (Loss) before Working Capital Changes	<u>(32.89)</u>	<u>85.40</u>
Adjustments for:		
Increase/(Decrease) in Trade Payables	(501.67)	(42.52)
Increase/(Decrease) in Other Current Liabilities	12.03	(24.78)
Increase/(Decrease) in Provisions	(19.73)	8.77
(Increase)/Decrease in Trade Receivables	298.08	181.74
(Increase)/Decrease in short term loans & advances	-	-
Increase/(Decrease) in Borrowing	-	-
(Increase)/Decrease in inventories	(4.29)	(18.95)
(Increase)/Decrease in other current assets	1.57	1.12
Cashflow generated from Operating Activities	<u>(246.88)</u>	<u>190.78</u>
Income Tax Paid (Net of Refund)	-	11.26
Net Cashflow generated from Operating Activities A	<u>(246.88)</u>	<u>179.52</u>
B Cash flow from Investment Activities		
Purchase of Property , Plant and Equipment	(0.79)	(3.75)
Sale of Property , Plant and Equipment	-	-
Sale of Investments	-	-
Purchase of Investments	-	-
Share Application Money Received Back	-	-
Dividend Income	-	-
Net Cashflow generated from Investments Activities B	<u>(0.79)</u>	<u>(3.75)</u>
C Cash flow from Financing Activities		
Share Listing & Processing Fees		
Interest Expenses	(35.08)	(41.30)
(Increase)/Decrease in other non-current assets	-	-
(Increase) /Decrease in Short term Loans & Advances (Assets)	(4.34)	194.27
Increase /(Decrease) in Borrowings (Liabilities)	282.98	(330.14)
Net Change in Unsecured Loans Taken	-	-
Increase/(Decrease) in other financial liabilities	-	-
Net Cashflow generated from Financing Activities C	<u>243.55</u>	<u>(177.16)</u>
Net Change in Cash & Cash Equivalents (A+B+C)	<u>(4.11)</u>	<u>(1.40)</u>
Opening Cash & Cash Equivalents	9.05	10.45
Closing Cash & Cash Equivalents	<u>4.94</u>	<u>9.05</u>



To,
Board of Directors
M/s Vivanza Biosciences Limited

Report on the Audit of the Consolidated Annual Financial Results Opinion

We have audited the accompanying statement of quarterly and year to date consolidated financial results of **M/s Vivanza Biosciences Limited** ("Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter and year ended March 31, 2025, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of other auditors on separate audited financial statements of the subsidiary, the aforesaid consolidated annual financial results:

A. includes the annual financial results for the year ended 31st March 2025, of the following entities:

Sr. No.	Particulars	Name of the Entity
1.	Subsidiary	Vivanza Life sciences Private Limited

- B. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard and
- C. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the consolidated net Profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the 'ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and that obtained by the other auditor in terms of their report referred to in paragraph of the Other Matters section below, is sufficient and appropriate to provide a basis for our opinion.



Responsibility of Management for the Consolidated Annual Financial Results

The consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's management and Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these annual financial results that give a true and fair view of the financial position, financial performance, changes in equity

and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Directors of the Holding Company, as aforesaid. In preparing the consolidated annual financial results, the respective Board of Directors of the companies included in the Group is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is also responsible for overseeing the financial reporting process of each company.

Auditor's Responsibility for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the consolidated annual financial results.

As a part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management
- Conclude on the appropriateness of Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or

conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern

- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any Significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all the relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards

We also performed procedures in accordance with the circular No CIRJCFD/CMD1/44/2019 issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable



Other Matters

We did not audit the annual financial statements of one subsidiary included in the Statement for the year ended on that date, as considered in the Statement. These Annual Financial Statements have been audited by other auditor whose Audit report has been furnished to us by the management, and our opinion in so far as it relates to the amounts and disclosures Include in respect of this subsidiary is based solely on the audit report of such other auditor, and the procedure performed by us as stated in paragraph above.

For, SHIVAM SONI & Co.
Chartered Accountants
FRN: 152477W



Shivam

CA Shivam Soni
Proprietor
Membership No: 178351
UDIN : 25178351BMIRIM2273

Place: Ahmedabad
Date: 12th May, 2025

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

CIN : L24110GJ1982PLC005057

Email : info@vivanzabioscience.com Website : www.vivanzabiosciences.com Ph.No. : 079-26870953


STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2025

Particulars		Quarter Ended			(Rs. in Lacs except per share data)	
		31-03-2025	31-12-2024	31-03-2024	Year Ended	
		Audited	Unaudited	Audited	31-03-2025	31-03-2024
				Audited	Audited	
1	Income from Operations					
	(a) Revenue from operations					
	(b) Other Income	48.30	150.05	442.25	742.33	2783.5
	Total Income	4.62	1.03	-2.92	6.15	5.4
2	Expenses	52.91	151.08	439.33	748.48	2788.9
	(a) Cost of Materials consumed					
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.0
	(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	47.79	147.26	411.82	707.74	2548.2
	(d) Employee benefits expense	69.56	-36.30	23.80	-25.68	46.8
	(e) Finance Cost	15.23	13.28	10.21	57.51	45.1
	(f) Depreciation and amortisation expense	7.98	8.72	9.19	35.14	41.3
	(g) Other expenses	0.28	0.41	1.00	1.40	1.2
	Total Expenses	11.04	13.44	9.91	38.94	36.7
3	Profit/(loss) before exceptional items and tax (1-2)	151.88	146.81	465.94	815.05	2719.3
4	Exceptional Items	-98.97	4.27	-26.61	-66.57	69.5
5	Profit/(Loss) before tax (3-4)	0.00	0.00	0.00	0.00	0.0
6	Tax Expense	-98.97	4.27	-26.61	-66.57	69.5
	(a) Current tax					
	(b) Deferred tax	0.70	0.00	14.90	0.70	14.9
	Total Tax Expenses	0.14	0.00	-0.11	0.14	-0.1
7	Profit / (Loss) for the period from continuing oprations (5-6)	0.84	0.00	14.79	0.84	14.7
8	Profit (Loss) from discontinuing oprations	-99.81	4.27	-41.40	-67.41	54.7
9	Tax Expense of discontinuing oprations	0.00	0.00	0.00	0.00	0.0
10	Profit (Loss) from discontinuing oprations (after tax)(8-9)	0.00	0.00	0.00	0.00	0.0
11	Other Comprehensive Income					
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.0
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.0
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.0
	ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.0
	Other Comprehensive Income for the period	0.00	0.00	0.00	0.00	0.0
12	Total Comprehensive Income for the period	0.00	0.00	0.00	0.00	0.0
13	Paid-up equity share capital (Face value of Rs. 1/- each)	-99.81	4.27	-41.40	-67.41	54.7
14	Other Equity	400	400	400	400	400
15	Earnings Per Share (before extraordinary items) (not annualised):					
	(a) Basic					
	(b) Diluted	-0.25	0.01	-0.10	-0.17	0.14
16	Earnings Per Share (after extraordinary items) (not annualised):					
	(a) Basic					
	(b) Diluted	-0.25	0.01	-0.10	-0.17	0.14


Notes:

- The above standalone audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on May 09, 2025. The Audit under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Audit Report does not contain any observation which could have an impact on the results for the quarter/year ended March 31, 2025.
- The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.
- The Company is in the business of Pharmaceuticals and Agro Trading & Consultancy activities.

For, VIVANZA BIOSCIENCES LIMITED


JAYENDRA MEHTA
 MANAGING DIRECTOR

DIN : 08210602



Date : 12/05/2025
Place : Ahmedabad

VIVANZA BIOSCIENCES LIMITED			
STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES			
(Rs.in Lacs)			
Particulars		As at 31/03/2025	As at 31/03/2024
A	ASSETS		
	1 Non-current Assets		
(a)	Property, Plant and Equipment	69.88	70.49
(b)	Other Intangible assets (including	163.54	163.54
(c)	Capital work in progress	-	-
(d)	Intangible assets under developme	-	-
(e)	Financial Assets :	-	-
(i)	Investments	0.25	0.25
(ii)	Deferred tax assets (Net)	0.06	0.21
(iii)	Loans	113.82	82.24
(f)	Other non-current assets	59.33	59.33
	Sub-total - Non-current Assets	406.89	376.06
	2 Current Assets		
(a)	Inventories	226.31	200.63
(b)	Financial Assets :		
(i)	Investments	-	-
(ii)	Trade Receivables	805.93	1,153.94
(iii)	Cash and Cash Equivalents	11.69	16.69
(iv)	Loans	164.35	162.22
(c)	Other current assets	30.15	40.60
	Sub-total - Current Assets	1,238.43	1,574.08
	TOTAL - ASSETS	1,645.32	1,950.14
B	EQUITY AND LIABILITIES		
	Shareholders' Funds		
(a)	Share Capital	400.00	400.00
(b)	Other Equity	(3.59)	63.83
	Sub-total - Shareholders' Funds	396.41	463.83
	1 Liabilities		
	Non-current Liabilities		
(a)	Financial Liabilities :		
(i)	Borrowings	333.49	268.20
(b)	Deferred Tax Liabilities (Net)	-	-
(c)	Provisions	-	-
(d)	Other Non - Current Liabilities	-	-
	Sub-total - Non-current liabilities	333.49	268.20
	2 Current Liabilities		
(a)	Financial Liabilities :		
(i)	Borrowings	531.73	248.75
(ii)	Trade Payables	261.81	823.47
(iii)	Other Financial Liabilities	-	-
(b)	Provisions	5.91	28.61
(c)	Other Current Liabilities	115.97	117.28
	Sub-total - Current Liabilities	915.42	1,218.12
	TOTAL - EQUITY AND LIABILITIES	1,645.32	1,950.14



[Handwritten signature]

VIVANZA BIOSCIENCES LIMITED
Consolidated Cashflow Statement

Particulars	(Rs.in Lacs)	
	01-04-2024 to 31-03-2025	01-04-2023 to 31-03-2024
A Cash flow from Operating Activities		
Net Profit Before Tax	(66.57)	69.52
Adjustments for:		
Add Depreciation	1.40	1.21
Less Dividend Income	-	-
Add Interest Expense	35.14	41.30
Less Short Term Capital Gain (Mutual Fund)	-	-
Operating Profit / (Loss) before Working Capital Changes	<u>(30.03)</u>	<u>112.03</u>
Adjustments for:		
Increase/(Decrease) in Trade Payables	(561.66)	(131.46)
Increase/(Decrease) in Other Current Liabilities	(1.31)	49.17
Increase/(Decrease) in Provisions	(22.70)	12.77
(Increase)/Decrease in Trade Receivables	348.01	94.01
(Increase)/Decrease in short term loans & advances	(31.58)	(81.14)
Increase/(Decrease) in Borrowing	65.29	124.92
(Increase)/Decrease in inventories	(25.68)	46.83
(Increase)/Decrease in other current assets	10.45	(7.88)
Cashflow generated from Operating Activities	(249.20)	219.25
Income Tax Paid (Net of Refund)	0.70	14.90
Net Cashflow generated from Operating Activities A	(249.90)	204.35
B Cash flow from Investment Activities		
Purchase of Property , Plant and Equipment	(0.79)	(3.75)
Sale of Property , Plant and Equipment	-	-
Sale of Investments	-	-
Purchase of Investments	-	-
Share Application Money Received Back	-	-
Dividend Income	-	-
Net Cashflow generated from Investments Activities B	(0.79)	(3.75)
C Cash flow from Financiag Activities		
Share Listing & Processing Fees		
Interest Expenses	(35.14)	(41.30)
(Increase)/Decrease in other non-current assets	-	0.00
(Increase) /Decrease in Short term Loans & Advances (Assets)	(2.12)	250.95
Increase /(Decrease) in Borrowings (Liabilities)	282.97	(407.67)
Increase/(Decrease) in non current liabilities	-	-
Increase/(Decrease) in other financial liabilities	-	-
Net Cashflow generated from Financing Activities C	245.70	(198.02)
Net Change in Cash & Cash Equivalents (A+B+C)	(4.99)	2.58
Opening Cash & Cash Equivalents	16.68	14.10
Closing Cash & Cash Equivalents	11.69	16.68



[Handwritten Signature]

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057

“Annexure- B”

The Details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Applicable Circulars are given below:

Sr. No.	Particulars	Details
1.	Reason for Change viz. Appointment, re-appointment, resignation, removal, death or otherwise	Appointment.
2.	Date of Appointment/ re-appointment/cessation & terms of appointment/ re-appointment	12 th May, 2025.
3.	Brief Profile (in case of appointment)	Mr. Rahul Doshi is Qualified Chartered Accountant holding certificate of Practice since 2004. He also holds Bachelor of Commerce. He is also DISA Qualified.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057

“Annexure- C”

The Details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Applicable Circulars are given below:

Sr. No.	Particulars	Details
1.	Reason for Change viz. Appointment, re-appointment, resignation, removal, death or otherwise	Appointment.
2.	Date of Appointment/ re-appointment/cessation & terms of appointment/ re-appointment	12 th May, 2025.
3.	Brief Profile (in case of appointment)	Mr. Chintan Patel is the proprietor of Chintan Patel & Associates, Company Secretaries. He holds a postgraduate degree in Commerce and is a Fellow Member of the Institute of Company Secretaries of India (ICSI). As a Practicing Company Secretary with more than 5 years of experience, he has extensive expertise in Corporate Laws, Securities Laws, Corporate Governance matters, Legal Due Diligence, Joint Ventures, Foreign Collaborations, Mergers and Acquisitions, Due Diligence, Listings, IPO related work , Capital Market Transactions other allied legal areas.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057

“Annexure – D”

The Details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Applicable Circulars are given below:

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment.
2.	Date of appointment & terms of appointment	Board, in its meeting held on May 12, 2025 has appointed Mr. Hitesh Rijwani, Non Executive Independent Director of the Company for a first term of 5 (five) consecutive years commencing from May 12, 2025, subject to approval of shareholders of the Company to be obtained within three months hereof.
3.	Brief Profile	He has completed his Bachelors in Commerce and LL.B from Gujarat University in the year 2021 and 2024 respectively. He has knowledge of Corporate Secretarial related work. He will bring expertise in compliance oversight, ensuring that corporate policies and procedures align with legal and regulatory frameworks in the Company.
4.	Disclosure of relationship between directors (in case of appointment of a director)	Mr. Hitesh Rijwani is not related to any other Director of the Company.
5.	Affirmation that Director is not debarred from the holding office of director by virtue of any SEBI order or authority	Mr. Hitesh Rijwani is not debarred from the holding the office of director by virtue of any SEBI order or any other such authority.

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057

“Annexure – E”

RECONSTITUTION OF COMMITTEE/S OF THE BOARD W.E.F 12TH MAY, 2025:

I. AUDIT COMMITTEE:

Sr. No.	Name of the Director	Status in Committee	Nature of Directorship
1.	Mr. Hitesh Rijwani	Chairman	Non-Executive Independent Director
2.	Ms. Rina Kumari	Member	Non-Executive Independent Director
3.	Mr. Jayendra Mehta	Member	Executive Director

II. NOMINATION AND REMUNERATION COMMITTEE:

Sr. No.	Name of the Director	Status in Committee	Nature of Directorship
1.	Mr. Hitesh Rijwani	Member	Non-Executive Independent Director
2.	Ms. Rina Kumari	Chairperson	Non-Executive Independent Director
3.	Mr. Parikh H. A.	Member	Non-Executive Director

III. STAKEHOLDER’S RELATIONSHIP COMMITTEE:

S.No	Name of the Director	Status in Committee	Nature of Directorship
1.	Ms. Rina Kumari	Chairperson	Non-Executive Independent Director
2.	Mr. Hitesh Rijwani	Member	Non-Executive Independent Director
3.	Mr. Jayendra Mehta	Member	Executive Director